Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136). (Q39615830)
Jump to navigation
Jump to search
scientific article published on February 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136). |
scientific article published on February 2009 |
Statements
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136) (English)
P Yeni
A Lamarca
D Berger
P Cimoch
P Salvato
F M Smaill
E Teofilo
S J Madison
W G Nichols
K K Adkison
T Bonny
J Millard
D McCarty
EPIC (CCR100136) study team